Showing results (321-330 of 673) with videos related to

Sort By:
Pageof 68
HIV Clinical Trials|May 29, 2002
Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 studyMartyn French, Janaki Amin, Norman Roth, et al.
HIV Clinical Trials|May 29, 2002
Technologies for measuring HIV-1 drug resistanceBarbara Schmidt, Klaus Korn, Hauke Walter
HIV Clinical Trials|May 29, 2002
Genetic mechanisms of resistance to protease inhibitors and entry inhibitorsVincent Soriano, Carmen de Mendoza
HIV Clinical Trials|December 17, 2013
Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trialValerianna K Amorosa, Anne Luetkemeyer, Minhee Kang, et al.
HIV Clinical Trials|July 30, 2016
Predictors of late virologic failure after initial successful suppression of HIV replication on efavirenz-based antiretroviral therapyIsaac Singini, Thomas B Campbell, Laura M Smeaton, et al.
HIV Clinical Trials|July 2, 2015
Long-term immunologic and virologic responses on raltegravir-containing regimens among ART-experienced participants in the HIV Outpatient StudyKate Buchacz, Ryan Wiegand, Carl Armon, et al.
HIV Clinical Trials|October 11, 2005
Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patientsTrevor Hawkins, Cindy Geist, Ben Young, et al.
HIV Clinical Trials|October 11, 2005
Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activityMatilde Sánchez-Conde, Carmen de Mendoza, Inmaculada Jiménez-Nacher, et al.
HIV Clinical Trials|May 11, 2006
Cardiovagal autonomic dysfunction in relation to HIV-associated lipodystrophyDominic C Chow, Robert Wood, Andrew Grandinetti, et al.
HIV Clinical Trials|February 1, 2005
Efficacy and safety of abacavir plus lamivudine versus didanosine plus stavudine when combined with a protease inhibitor, a nonnucleoside reverse transcriptase inhibitor, or both in HIV-1 positive antiretroviral-naive personsR D MacArthur, L Chen, G Peng, et al.
Pageof 68